Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kairos Pharma, LTD. (KAPA)

Kairos Pharma reports positive interim Phase 2 data for ENV-105 in prostate cancer

Positive Impact 4 of 5 other Written later

Kairos Pharma said interim Phase 2 data showed a statistically significant difference in progression-free survival for patients treated with ENV-105 plus apalutamide compared with apalutamide alone. The company also modified the trial protocol to enroll patients earlier in disease progression, with completion targeted in or before the fourth quarter of 2027.

Key points

  • Median progression-free survival was 17.7 months with ENV-105 plus apalutamide versus 2 months with apalutamide alone (P=0.0008).
  • The modified protocol enrolls patients after a PSA increase following upfront androgen signaling inhibitor treatment, randomized to enzalutamide alone or with ENV-105.
  • Kairos Pharma targets completing the Phase 2 trial in or before the fourth quarter of 2027.

The filing

CompanyKairos Pharma, LTD. (KAPA)
Form8-K, current report
Filed with the SECOct 6, 2026, 7:30 AM ET
Accession number0001493152-26-045844

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.